WORTH THE WAIT: IMPAIR-ID™ MARIJUANA IMPAIRMENT SCREENING IS HERE

Scottsdale, Arizona - August 19, 2019 - ZXEREX® Corporation announces IMPAIR-ID™ Marijuana Impairment Screening, a new non-invasive, fast, inexpensive test to detect “impairment.” IMPAIR-ID incorporates technology developed by a team of scientists and engineers from Arizona State University and Barrow Neurological Institute (Dignity Health). 

IMPAIR-ID™ utilizes patented technology to analyze voluntary and involuntary eye movements called saccades, and micro-saccades to detect temporary “impairment” associated with the effect of Marijuana on the brain.  The technology references a unique bio-signature to identify and classify temporary changes in the brain attributed to THC, the active ingredient of Marijuana.  When combined with an employer’s workplace safety program, IMPAIR-ID™ is geared to reduce injuries, absenteeism, and productivity losses while serving as a deterrent. Because IMPAIR-ID™ only takes a few minutes, screening for Marijuana impairment can be done as often as desired, especially for employees in high risk environments.

Currently, the only way employers can insulate their businesses from drug abuse is to perform pre-employment and random drug testing of saliva, urine or hair.  The problem with these tests for Marijuana is that they don’t tell if a worker is currently intoxicated or impaired, because the active ingredient (THC) can remain in the body from 3 to 30 days following use.  Positive tests in States where Marijuana is legal are forcing employers to rethink traditional drug testing to deal with Marijuana since the presence of Marijuana in a body fluid is not a useful indicator of “impairment.” 

Zxerex plans to address the needs of employers to be followed by public safety and consumers, including parents concerned about potential drug use by children.

For further information, go to IMPAIR-ID.COM, or email our IMPAIR-ID™ team at rb@zxerex.com or call (480) 518-9905.

ZXEREX® ANNOUNCES ISSUANCE OF U.S. PATENT FOR NON-INTRUSIVE IMPAIRMENT DETECTION OF DRUGS, INCLUDING MARIJUANA

Scottsdale, Arizona - August 13, 2019 ZXEREX® CORPORATION is pleased to announce the issuance of US Patent 10,376,183, “Systems and methods for non-intrusive drug impairment detection,” on August 13, 2019. The patent includes, “systems and methods for detecting onset, presence, and progression of particular states, including intoxication, include observing eye movements of a subject and correlating the observed movements to known baseline neurophysiological indicators of intoxication.”

The company will soon release, IMPAIR-ID™, its new. much needed, disruptive screening test technology to identify temporary neurological “impairment” related to marijuana and other drugs.  The technology was developed by a team of scientists at Arizona State University and Barrow Neurological Institute (Dignity Health).  The Company has developed a Marijuana bio-signature and a means of detecting impairment,  rapidly, conveniently, and inexpensively.

Zxerex plans to apply this technology to workplace safety, and thereafter, to support public safety and consumers, including parents concerned about potential drug use at home.

For further information, email the IMPAIR-ID™ team at ZXEREX® CORPORATION at rb@zxerex.com or call (480)518-9905.

IMPAIRMENT vs. PRESENCE: Reaction to the Proposed Arizona Marijuana Legalization Initiative (2020)

Scottsdale, Arizona - August 11, 2019 - According to the Arizona Republic, the “Arizona marijuana measure faces opposition from business community, politicians,” (https://www.azcentral.com/story/news/politics/arizona/2019/08/10/legal-marijuana-measure-faces-opposition-business-politicians/1972386001/). The details of the proposed initiative are now available for the first time,  (http://archive.azcentral.com/persistent/icimages/news/2019-0809%20%5BFINAL%5D%20Smart%20and%20Safe%20Act%20Initiative%20Text%20(00451371xC217C).PDF).

 The Arizona business community and lawmakers will likely continue to oppose recreational marijuana due to the disconnect between federal and state laws; the impact on workplace and highway safety; and, the potential shortage of qualified workers who may denied employment because they test positive on employment drug testing.

Marijuana use has been shown to increase workplace injuries, increase absenteeism and decrease worker productivity.  The number of workers disqualified due to positive pre-employment testing will likely increase, making staffing in this tight market even more difficult.  Since Marijuana can remain in the body from 3 to 30 days after its use, positive drug tests continue to rise in states where recreational marijuana has been adopted. 

From a safety perspective, impairment due to Marijuana in the workplace is a serious concern for all employers and their employees.  Zxerex Corporation has developed IMPAIR-ID™ a rapid, non-invasive, low cost, impairment screening test to identify impairment due to Marijuana. The technology is expected to deter Marijuana use in the workplace, and when combined with an employer’s workplace safety program to decrease injuries and reduce absenteeism.

Zxerex®, when combined with an employer’s safety program, can help to identify impairment and manage risk.

For more information, please email the IMPAIR-ID™ team at rb@zxerex.com or call 480-518-9905.

A NEW DETERRENT: MARIJUANA AND IMPAIRMENT IN THE WORKPLACE

Scottsdale, Arizona - August 5, 2019 - IMPAIR-ID™ powered by ZXEREX® is a new disruptive screening test to identify temporary neurological “impairment” related to marijuana use.  The technology was developed by a team of scientists at Arizona State University and Barrow Neurological Institute (Dignity Health). 

Zxerex uses traditional statistics, machine learning and artificial intelligence to identify and classify neurological changes attributed to drugs, such as THC, the active ingredient of Marijuana. The Company has developed a Marijuana Bio-signature and a methodology to detect temporary neurological “impairment,”  rapidly, conveniently, and inexpensively.

Drug use is a major concern in the workplace and has been reported to be associated with increase absenteeism, higher workplace injury and decrease in productivity.   Zxerex offers a way to address these problems. When combined with an existing workplace safety program, Zxerex technology provides an important DETERRENT that documents marijuana use and “impairment.”

Zxerex will initially apply this technology for workplace safety, and thereafter, the company plans to support public safety and consumers, including parents concerned about potential drug use by children.

For further information, contact the IMPAIR-ID™ team at Zxerex, rb@zxerex.com or (480)518-9905.

ZXEREX®: HELPING EMPLOYERS WITH THE RISING COST OF DRUG ABUSE

Scottsdale, Arizona - July 30, 2019 - EHS Today has reported that as of 2014, losses in workplace productivity due to drug abuse among America employers exceeds $81 billion dollars annually. The productivity of addicted employee is estimated to be only two thirds of normal workers.

Drug abuse is spiraling out of control with the opioid crisis and recreational marijuana use leading the way.  Currently, the only way in which employers can insulate their businesses from drug abuse is to perform periodic drug testing of saliva, urine or hair. The problem with these tests is that they detect if drugs within a time frame of hours, days, or weeks but do not tell if a worker is currently intoxicated or impaired.  Impaired workers are often responsible for increased injuries and casualty loss.

Zxerex® (Scottsdale, AZ) is developing IMPAIR-ID™ a rapid, non-invasive screening test that takes just minutes to detect whether an employee my be impaired.  The test involves eye-tracking analysis and can be performed even daily, and certainly more often than in a random urine tests program. 

The screening test analyzes voluntary and involuntary eye movements called saccades and micro-saccades.  When under the influence of  certain drugs, the drug effect has a detectable signature which is recognized and reported by the system.  When combined with an employer safety program, Zxerex screening can help reduce workplace injuries, reduce lost time, and address productivity losses. 

For further information, contact Zxerex Corporation at www.zxerex.com.

MARIJUANA IMPAIRMENT SCREENING TECHNOLOGY SOON TO BE EXPANDED TO INCLUDE OPIOIDS

Scottsdale, Arizona - July 15, 2019 - ZXEREX® CORPORATION announces the development of a unique bio-signature that reveals temporary neurological impairment, strongly associated with the use of marijuana. Using a combination of traditional biostatistical analysis, deep machine learning, and artificial intelligence, ZXEREX will soon release IMPAIR-ID™, a screening technology that can identify marijuana intoxication.

This disruptive development provides a rapid, non-invasive, and inexpensive way to screening for workers with jobs in which marijuana use poses significant risk to themselves, co-workers, and the public.

When combined with a workplace safety program, this screening capability has the potential to reduce workplace accidents and injuries in manufacturing, construction, energy, transportation, and healthcare.

The company’s initial human subject research was performed at the SUNY Downstate Medical Center and Columbia University.

ZXEREX plans to conduct additional studies to identify bio-signatures for opioids in opioid-naïve and opioid-tolerant human subjects. In addition, the company will study the combined effects of alcohol and marijuana which are known to substantially increase risk. Prior research and analysis of highway fatalities in a recent GHSA study, funded by the Foundation for Advancing Alcohol Responsibility, showed in 2016, that 48.5% of fatalities that involved alcohol, also included other drugs such as marijuana, opioids or both.

The ability to identify impairment when combined with an employer’s safety program can help to reduce workplace injuries, lower absenteeism, lower casualty loss, and save lives. Zxerex hopes to play a very important role by helping employers with a safer workplace.

For further information, contact the IMPAIR-ID™ team at Zxerex, rb@zxerex.com or (480)518-9905.

EMPLOYER BREAKTHROUGH - MARIJUANA SCREENING – NEW TECHNOLOGY IDENTIFIES IMPAIRMENT, NOT JUST PRESENCE

Scottsdale, Arizona - July 1, 2019 - Workplace safety issues have increased as legalization of medical and recreational use has grown. According to the National Safety Council, Marijuana use has increased workplace injuries by 85% and absenteeism by 75%. It’s estimated that productivity loss due to drug use has cost business a whopping $270B in 2017. The American Automobile Association and others have noted that driving after smoking Marijuana doubles the risk of a fatal crash and it is even worse when combined with alcohol.

ZXEREX® was spun out of Arizona State University (ASU) and Barrow Neurological Institute where the technology was developed by a team of well-known neuroscientists. Human studies were completed at SUNY Downstate Medical Center and Columbia.

ZXEREX is rolling out IMPAIR-ID™, a rapid non-invasive screening test that identifies impairment related to Marijuana within minutes. Traditional urine, saliva, blood and hair tests show only the presence of a drug but do not identify impairment. When tests are positive, the drug may have been used days or weeks ago, whereas ZXEREX identifies neurological impairment due to marijuana’s effect on the brain. When combined with a workplace safety program, Zxerex expects that its technology will help as a deterrent to reduce absenteeism, injuries and casualty losses, and help to improve worker productivity.

For further information, send an email to the ZXEREX team, rb@zxerex.com or call us at (480)518-9905.